Clinical trials: Headache Disorder
Episodic Cluster Headache, Chronic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL…
- Trial name
- NCT02797951
- Testing
- Galcanezumab
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Headache, Tumor
Dexmedetomidine and Propofol for Pediatric MRI Sedation
The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia…
- Conditions
- Headache, Tumor, Seizure Disorder, Neurofibromatoses
- Trial name
- NCT03513757
- Testing
- propofol, Dexmedetomidine, Glycopyrrolate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Medication Overuse Headache
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
- Trial name
- NCT02583425
- Testing
- DFN-11 Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine
Ictal and Interictal Inflammatory Markers in Migraine
The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches.
- Trial name
- NCT01138150
- Testing
- Treximet
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Johns Hopkins University
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine
Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs
Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has been noted in several studies that in patients with migraine, seventy nine percent of the patients experienced allodynia on the facial…
- Trial name
- NCT00386880
- Testing
- Sounds
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Thomas Jefferson University
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Persian Gulf Syndrome
Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)
The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects.
- Trial name
- NCT00810368
- Testing
- Carnosine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Georgetown University
Acute Migraine
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
- Trial name
- NCT05371652
- Testing
- Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Where
- 26 sites in China
- Volunteers
- 241 people
- Sponsor
- Pfizer
Cyclic Vomiting Syndrome
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
- Trial name
- NCT04645953
- Testing
- 3mg AZ-010, 1mg AZ010
- Where
- 18 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine Disorders
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents for the acute treatment of migraine.
- Trial name
- NCT00488514
- Testing
- Combination Tablet of Treximet (sumatriptan/naproxen sodium)
- Where
- 77 sites in United States
- Volunteers
- 656 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
Migraine is a neurological disease characterized by severe and recurrent headaches. Children and adolescents with migraine often present to the emergency department (ED) with acute attacks, where migraine accounts for up to ~30%…
- Trial name
- NCT05102591
- Testing
- Ketorolac, Metoclopramide, Active Remote Electrical Neuromodulation Device
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary
Headache, Migraine
Sphenopalatine Nerve Block for Headache Tx360
The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.
- Trial name
- NCT01939314
- Testing
- Bupivacaine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Indiana University
Migraine, Depression
Brief Behavioral Intervention for Comorbid Migraine and Depression
The purpose of this research study is to examine whether a one-day group workshop, integrating principles from Acceptance and Commitment Therapy with Migraine Education, will result in improvements in depressive symptoms and…
- Trial name
- ACT-IM (NCT01775852)
- Testing
- ACT-IM
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Lilian N. Dindo
Migraine
Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
The primary purpose of this study is to determine whether erenumab is safe and well tolerated in healthy adults and migraine patients.
- Trial name
- NCT01723514
- Testing
- Erenumab
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Migraine
Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks.
- Trial name
- NCT03712917
- Testing
- Greater Occipital Nerve Block, Topiramate, Flunarizine
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Ataturk University